Clinical Trial: Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Lymphoma, Primary Effusion
Study Type: INTERVENTIONAL
Official Title: A Phase II Study of Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma
Brief Summary:
Background:Primary effusion lymphoma (PEL) is an aggressive form of cancer that affects cells in the immune system and lymph nodes.How PEL develops is not well understood, and this disease does not respond well to standard treatments for other types of lymphomas.Objective:To test a drug treatment (daratumumab SC) in people with PEL.Eligibility:People aged 18 and older with PEL.Their PEL must have failed to respond to therapy or they must be unable to receive standard treatment for the disease.Design:Participants…
Read more